Author： Topiol Sid
Publisher： Informa Healthcare
ISSN： 1746-0441
Source： Expert Opinion on Drug Discovery, Vol.8, Iss.6, 2013-10, pp. : 607-620
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Theoretical Arguments for the Discounting of Health Consequences: Where Do We Go from Here?
By Lazaro A.
PharmacoEconomics, Vol. 20, Iss. 14, 2002-01 ,pp. :
Access to resources
Recommend
Therapy for Osteosarcoma: Where Do We Go From Here?
Pediatric Drugs, Vol. 10, Iss. 5, 2008-01 ,pp. :
Drug-Resistant Tuberculosis: What Do We Do Now?
By Telenti A.
Drugs, Vol. 59, Iss. 2, 2000-02 ,pp. :
Progress in Colorectal Cancer Chemotherapy: How Far Have We Come, How Far to Go?
By Royce M.E.
Drugs & Aging, Vol. 17, Iss. 3, 2000-09 ,pp. :